Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
about
Hepatic late adverse effects after antineoplastic treatment for childhood cancerSafety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.Prospective predictors of return to work in the 5 years after hematopoietic cell transplantationConditioning regimens for hematopoietic cell transplantation: one size does not fit allTumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.Chronic myelogenous leukemia: treatment and monitoring.Busulfan in hematopoietic stem cell transplantationThe war on cancer: a report from the front linesLate toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children.High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature.Myeloablative conditioning regimens for AML allografts: 30 years later.Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CYFeasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancyAllogeneic transplantation for chronic myelogenous leukemia.Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings.Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.Acute graft-versus-host disease: from the bench to the bedside.Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Late complications after hematopoietic stem cell transplantation.Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia.Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation.Conditioning regimens in acute myeloid leukemia.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of >2 years.Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity.Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation.The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
P2860
Q24235525-859702C8-F715-4E68-84D3-70159E4C9785Q33348605-F97891F8-4D46-42FC-B549-81E0CC873E05Q33680218-5208C87E-CB3D-411B-A1F9-07392600CD38Q33786982-997341B0-EB41-4B13-861E-C16C1357F742Q33917170-708925CC-E6F0-4602-BA23-96F37266F045Q34288677-ED62BFD2-386A-4070-BD62-91DC73476EEEQ34617628-2152EABB-31C7-4B04-8543-7ED17EC8D383Q34668052-4143D38D-C5C8-4830-A52B-22B5C6CF5390Q35103643-20112C08-827E-42E7-BE06-329FD6008731Q35110623-3ECF8814-4537-43C7-B6EF-DB685899378EQ35112199-53107DB0-58A1-414B-B8D3-29C53B1C0C2DQ35136616-CF64FE81-02EF-4EF8-ADAA-567CFA9C9AB2Q35202316-2644A921-FEC0-42A9-93CD-61B7D68F552AQ35555709-8C252B4B-C3D8-4F5D-91DA-E06CD1110095Q35574536-C70ED6C6-4C6B-48FA-A8DB-30851EC24653Q35633858-82641AC6-C011-431E-B4CB-D52F935576CFQ35739130-7C123D42-2F69-462E-BDAD-7C503A869994Q35809873-C2EFB89A-6218-48CA-BF55-8C8A7D7F6B17Q36269924-69E58035-A1CA-4A0A-9721-45205651D202Q37061964-5C70B2CA-E233-42AE-8339-5DBB839231FBQ37140698-D804450B-3EE7-4137-ADCA-E5CC898D4506Q37181682-A3B71EED-C61D-48BB-B976-BE33FAADB9A9Q37370649-061FDCEB-65AA-4A64-89FD-D8E3E6A2BFC0Q37370651-0343C304-CBA9-4CBB-8309-6E1268581D10Q37420496-EE58CC54-C225-43F7-892B-CDE76D8D802EQ37810098-32F4D484-C488-423D-B6B8-8A16726EAF39Q37810122-4A6FD703-E445-4302-B2B4-0702DEC19DC2Q37828009-AC36AC48-222D-47BC-9400-B788E82581BCQ38015268-0ED0E365-93D7-4B94-8CBC-D9E96F8FB5B2Q38105635-7BF31D87-E67A-4A1E-8692-B2B3BC4C9275Q38229633-812B3B83-9480-4507-A67B-9AB564E51A64Q38248427-E4F0BA8A-3A5B-488E-AFA7-088B99A075D2Q39306717-976A8588-FFAA-47A1-8317-462A4EE83715Q39376553-78BC5749-E704-4973-854B-2AD15A4FBC83Q41039242-AC7558F5-2DC4-4755-9F4D-03FB357D5298Q41607636-9723343A-E774-4AB9-B453-F5C2B3F0039AQ42380314-B581CED7-8A2B-4372-858A-DCDF549E4424Q44383228-2CB11FCA-7917-4F2E-805B-E13E76983D55Q44571762-0BA3544F-9BC2-4CD8-BBD9-9F9E29C90717Q44571765-4310C5BF-2AE5-4DF9-82BE-09ED91BD532F
P2860
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Busulfan plus cyclophosphamide ...... ow-up of 4 randomized studies.
@en
Busulfan plus cyclophosphamide ...... ow-up of 4 randomized studies.
@nl
type
label
Busulfan plus cyclophosphamide ...... ow-up of 4 randomized studies.
@en
Busulfan plus cyclophosphamide ...... ow-up of 4 randomized studies.
@nl
prefLabel
Busulfan plus cyclophosphamide ...... ow-up of 4 randomized studies.
@en
Busulfan plus cyclophosphamide ...... ow-up of 4 randomized studies.
@nl
P2093
P1433
P1476
Busulfan plus cyclophosphamide ...... ow-up of 4 randomized studies.
@en
P2093
Devergie A
Michallet M
Remberger M
Sullivan KM
P304
P356
10.1182/BLOOD.V98.13.3569
P407
P577
2001-12-01T00:00:00Z